Cargando…

Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real‐World Practice

Several immune checkpoint inhibitor therapies (CPIs) have been approved to treat metastatic urothelial cell carcinoma (mUC). Because of the favorable toxicity profile of CPI compared with chemotherapy, oncologists may have a low threshold to prescribe CPI to patients near the end of life. We evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parikh, Ravi B., Galsky, Matthew D., Gyawali, Bishal, Riaz, Fauzia, Kaufmann, Tara L., Cohen, Aaron B., Adamson, Blythe J.S., Gross, Cary P., Meropol, Neal J., Mamtani, Ronac
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656487/ https://www.ncbi.nlm.nih.gov/pubmed/30944183 http://dx.doi.org/10.1634/theoncologist.2019-0039

Ejemplares similares

Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial Cancer
por: Mamtani, Ronac, et al.
Publicado: (2023)

Impact of Label Restriction on Checkpoint-Inhibitor Use in Bladder Cancer and Changes in Mortality
por: Vader, Daniel T, et al.
Publicado: (2022)

Evaluating the Impact of Oncology Care Model Reporting Requirements on Biomarker Testing and Treatment
por: Castellanos, Emily H., et al.
Publicado: (2020)

Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone
por: Marar, Mallika, et al.
Publicado: (2022)

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
por: Parikh, Ravi B., et al.
Publicado: (2023)

Accuracy of a Text Intervention to Minimize the Burden of Cancer Care Among Patients Treated With Immune Checkpoint Inhibitors
por: Bange, Erin M., et al.
Publicado: (2022)

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)
por: El-Deiry, Wafik S., et al.
Publicado: (2019)

Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma
por: Doshi, Gurjyot K., et al.
Publicado: (2023)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018
por: Parikh, Ravi B., et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
por: Patel, Aakash, et al.
Publicado: (2021)

Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations
por: Hannan, Zain, et al.
Publicado: (2021)

Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing
por: Harrigan, James J., et al.
Publicado: (2020)

Clinical Trial End Points in Severe COVID-19
por: Desai, Aakash, et al.
Publicado: (2020)

Intention to probe into the colonoscopy trial: Is it the procedure or the trial that failed?
por: Knopf, Kevin B., et al.
Publicado: (2022)

Cancer drugs in LMICs: cheap but unaffordable
por: Gyawali, Bishal
Publicado: (2017)

The OlympiAD trial: who won the gold?
por: Gyawali, Bishal
Publicado: (2017)

Low-value practices in oncology contributing to financial toxicity
por: Gyawali, Bishal
Publicado: (2017)

Me, Too
por: Gyawali, Bishal
Publicado: (2016)

Letter to Editor-response: placebo response rates
por: Gyawali, Bishal
Publicado: (2023)

Bridging the divide between clinical research and clinical care in oncology: An integrated real-world evidence generation platform
por: Bourla, Ariel B., et al.
Publicado: (2021)

Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma
por: Ravi, Praful, et al.
Publicado: (2022)

The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
por: Houssiau, Hélène, et al.
Publicado: (2022)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma
por: Aicher, Wilhelm K., et al.
Publicado: (2021)

Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
por: Narayan, Vivek, et al.
Publicado: (2016)

Long-term Survival After Treating Cardiac Metastasis With Radiation and Immune Therapy: A Case Report
por: Arscott, W. Tristram, et al.
Publicado: (2018)

Inverse Probability of Treatment Weighting and Confounder Missingness in Electronic Health Record-based Analyses: A Comparison of Approaches Using Plasmode Simulation
por: Vader, Daniel T., et al.
Publicado: (2023)

Combination therapies involving checkpoint-inhibitors for treatment of urothelial carcinoma: a narrative review
por: Schulz, Gerald B., et al.
Publicado: (2021)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
por: Tsai, Chung-Ying, et al.
Publicado: (2021)

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
por: Parent, Pauline, et al.
Publicado: (2023)

Negative trials in ovarian cancer: is there such a thing as too much optimism?
por: Gyawali, Bishal, et al.
Publicado: (2016)

Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016
por: Khoja, Leila, et al.
Publicado: (2016)

Cancer treatment in the last 6 months of life: when inaction can outperform action
por: Gyawali, Bishal, et al.
Publicado: (2018)

What Global Oncology Needs: Mutual Learning and More Funding
por: Gyawali, Bishal, et al.
Publicado: (2018)

Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries
por: Gyawali, Bishal, et al.
Publicado: (2016)

Same Data; Different Interpretations
por: Gyawali, Bishal, et al.
Publicado: (2016)

Endpoints used in phase III randomized controlled trials of treatment options for COVID-19
por: Desai, Aakash, et al.
Publicado: (2020)

Assessing the benefits and harms of direct oral anticoagulants in patients with cancer for the prophylaxis and treatment of venous thromboembolism: a systematic review and meta-analysis
por: Desai, Aakash, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cg3t5tdbh0ctcpmk97i5ha7mo3